Peter Lloyd

4.1k total citations · 1 hit paper
52 papers, 2.9k citations indexed

About

Peter Lloyd is a scholar working on Immunology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Peter Lloyd has authored 52 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Immunology, 11 papers in Molecular Biology and 10 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Peter Lloyd's work include Monoclonal and Polyclonal Antibodies Research (9 papers), Inhalation and Respiratory Drug Delivery (9 papers) and Biosimilars and Bioanalytical Methods (5 papers). Peter Lloyd is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (9 papers), Inhalation and Respiratory Drug Delivery (9 papers) and Biosimilars and Bioanalytical Methods (5 papers). Peter Lloyd collaborates with scholars based in Switzerland, United States and United Kingdom. Peter Lloyd's co-authors include Bin Peng, Horst Schran, Gérard Flesch, Philipp Müller, Michael Hayes, Renaud Capdeville, Reid Rubsamen, W. Dieterle, Debra Resta and Moshe Talpaz and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Environmental Pollution.

In The Last Decade

Peter Lloyd

51 papers receiving 2.8k citations

Hit Papers

Clinical Pharmacokinetics of Imatinib 2005 2026 2012 2019 2005 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Clinical Pharmacokinetics of Imatinib
    2005 513 citations Bin Peng, Peter Lloyd et al. Clinical Pharmacokinetics profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Peter Lloyd Switzerland 27 802 552 424 420 402 52 2.9k
Éric Thervet France 38 384 0.5× 193 0.3× 766 1.8× 726 1.7× 378 0.9× 143 4.9k
Guy H. Neild United Kingdom 35 235 0.3× 294 0.5× 649 1.5× 796 1.9× 119 0.3× 123 4.1k
Noémie Jourde‐Chiche France 29 349 0.4× 177 0.3× 940 2.2× 508 1.2× 273 0.7× 122 3.7k
Anders Wåhlin Sweden 30 2.5k 3.1× 1.1k 1.9× 1.3k 3.0× 344 0.8× 604 1.5× 121 3.9k
Eric P. Cohen United States 44 471 0.6× 240 0.4× 1.0k 2.5× 1.1k 2.7× 893 2.2× 140 5.9k
Laurence M. Blendis Canada 48 365 0.5× 411 0.7× 403 1.0× 818 1.9× 306 0.8× 154 6.6k
Paolo Ventura Italy 29 430 0.5× 283 0.5× 592 1.4× 287 0.7× 155 0.4× 156 2.8k
William E. Smoyer United States 36 294 0.4× 399 0.7× 691 1.6× 435 1.0× 68 0.2× 116 3.5k
Jean‐Philippe Haymann France 33 410 0.5× 326 0.6× 858 2.0× 1.2k 2.9× 116 0.3× 164 3.8k
Graeme A. Macdonald Australia 38 288 0.4× 219 0.4× 906 2.1× 245 0.6× 475 1.2× 170 6.0k

Countries citing papers authored by Peter Lloyd

Since Specialization
Citations

This map shows the geographic impact of Peter Lloyd's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Lloyd with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Lloyd more than expected).

Fields of papers citing papers by Peter Lloyd

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Lloyd. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Lloyd. The network helps show where Peter Lloyd may publish in the future.

Co-authorship network of co-authors of Peter Lloyd

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Lloyd. A scholar is included among the top collaborators of Peter Lloyd based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Lloyd. Peter Lloyd is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Brickman, Chaim M., Peter Lloyd, Ashish Kalra, et al.. (2025). Verekitug, a Novel Antibody Antagonist to the TSLP Receptor in Adults with Asthma: A 32‐Week Randomized Phase 1b Multiple Ascending‐Dose Trial. Clinical Pharmacology & Therapeutics. 119(3). 782–790.
2.
Galligan, Carole L., et al.. (2022). Fine-tuned long-acting interleukin-2 superkine potentiates durable immune responses in mice and non-human primate. Journal for ImmunoTherapy of Cancer. 10(1). e003155–e003155. 40 indexed citations
3.
4.
Binder, Uli, William McDowell, Rita Tommasi, et al.. (2019). Half-life extension and non-human primate pharmacokinetic safety studies of i-body AD-114 targeting human CXCR4. mAbs. 11(7). 1331–1340. 22 indexed citations
5.
6.
Keller, Virginie, et al.. (2014). Impact of climate change and population growth on a risk assessment for endocrine disruption in fish due to steroid estrogens in England and Wales. Environmental Pollution. 197. 262–268. 14 indexed citations
7.
8.
Llewellyn, Neville, Peter Lloyd, Monika D. Jürgens, & Andrew C. Johnson. (2011). Determination of cyclophosphamide and ifosfamide in sewage effluent by stable isotope-dilution liquid chromatography–tandem mass spectrometry. Journal of Chromatography A. 1218(47). 8519–8528. 39 indexed citations
9.
Rabinowitz, Joshua D., et al.. (2006). Ultra-Fast Absorption of Amorphous Pure Drug Aerosols via Deep Lung Inhalation. Journal of Pharmaceutical Sciences. 95(11). 2438–2451. 53 indexed citations
10.
Peng, Bin, Peter Lloyd, & Horst Schran. (2005). Clinical Pharmacokinetics of Imatinib. Clinical Pharmacokinetics. 44(9). 879–894. 513 indexed citations breakdown →
11.
Rabinowitz, Joshua D., Peter Lloyd, William Shen, et al.. (2004). Fast Onset Medications through Thermally Generated Aerosols. Journal of Pharmacology and Experimental Therapeutics. 309(2). 769–775. 59 indexed citations
12.
Farr, Stephen J., Simon Warren, Peter Lloyd, et al.. (2000). Comparison of in vitro and in vivo efficiencies of a novel unit-dose liquid aerosol generator and a pressurized metered dose inhaler. International Journal of Pharmaceutics. 198(1). 63–70. 41 indexed citations
13.
Gonda, Igor, et al.. (1998). Inhalation delivery systems with compliance and disease management capabilities. Journal of Controlled Release. 53(1-3). 269–274. 34 indexed citations
14.
Sioufi, A., F. Marfil, J Cardot, et al.. (1998). The effect of age on the pharmacokinetics of valsartan. Biopharmaceutics & Drug Disposition. 19(4). 237–244. 34 indexed citations
15.
Cipolla, David, Stephen J. Farr, Igor Gonda, et al.. (1998). Design and Testing of Aerosol Delivery Systems for Reproducible Clinical Performance. Journal of Aerosol Medicine. 11(s1). S–84. 2 indexed citations
16.
Brookman, L, Paul Rolan, I S Benjamin, et al.. (1997). Pharmacokinetics of valsartan in patients with liver disease. Clinical Pharmacology & Therapeutics. 62(3). 272–278. 77 indexed citations
17.
Ward, Marcy, Laurence E. Mather, Stephen J. Farr, et al.. (1997). Morphine pharmacokinetics after pulmonary administration from a novel aerosol delivery system*. Clinical Pharmacology & Therapeutics. 62(6). 596–609. 50 indexed citations
18.
Rubsamen, Reid, et al.. (1997). The AERX™ Aerosol Delivery System. Pharmaceutical Research. 14(3). 354–357. 62 indexed citations
19.
Flesch, Gérard, Philipp Müller, & Peter Lloyd. (1997). Absolute bioavailability and pharmacokinetics of valsartan, an angiotensin II receptor antagonist, in man. European Journal of Clinical Pharmacology. 52(2). 115–120. 173 indexed citations
20.
Lloyd, Peter, Gérard Flesch, & W. Dieterle. (1994). Clinical Pharmacology and Pharmacokinetics of Oxcarbazepine. Epilepsia. 35(s3). S10–3. 121 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Éric Thervet Breakdown of academic impact, for papers by Guy H. Neild Breakdown of academic impact, for papers by Noémie Jourde‐Chiche Breakdown of academic impact, for papers by Anders Wåhlin Breakdown of academic impact, for papers by Eric P. Cohen Breakdown of academic impact, for papers by Laurence M. Blendis Breakdown of academic impact, for papers by Paolo Ventura Breakdown of academic impact, for papers by William E. Smoyer Breakdown of academic impact, for papers by Jean‐Philippe Haymann Breakdown of academic impact, for papers by Graeme A. Macdonald
Rankless by CCL
2026